Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 117, Issue 2, Pages 215-225
Publisher
Wiley
Online
2015-03-28
DOI
10.1111/bju.13123
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.
- (2017) Francisco Emilio Vera-Badillo et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- (2017) Gurprataap Singh Sandhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone.
- (2017) Mark Creamer Scholz et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
- (2015) Robert J. van Soest et al. EUROPEAN UROLOGY
- Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial
- (2015) Fred Saad et al. EUROPEAN UROLOGY
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- (2015) Eleni Efstathiou et al. EUROPEAN UROLOGY
- Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
- (2015) H H Cheng et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
- (2014) Sebastian Christoph Schmid et al. ADVANCES IN THERAPY
- Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
- (2014) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Enzalutamide in European and North American men participating in the AFFIRM trial
- (2014) Axel S. Merseburger et al. BJU INTERNATIONAL
- Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
- (2014) David Thomson et al. EUROPEAN JOURNAL OF CANCER
- P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentre retrospective study
- (2014) O. Caffo et al. EUROPEAN UROLOGY SUPPLEMENTS
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Prostate cancer: ESMO Consensus Conference Guidelines 2012
- (2013) A. Horwich et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
- (2013) John M. Fitzpatrick et al. EUROPEAN UROLOGY
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells
- (2013) Félicie Cottard et al. PLoS One
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
- (2013) Frederik Birkebaek Thomsen et al. Scandinavian Journal of Urology
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Potentiation of Inflammatory CXCL8 Signalling Sustains Cell Survival in PTEN-deficient Prostate Carcinoma
- (2012) Pamela J. Maxwell et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- Characterising the castration-resistant prostate cancer population: a systematic review
- (2011) M. Kirby et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
- (2011) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
- (2011) Xiaotun Zhang et al. PLoS One
- New and emerging agents for the treatment of castration-resistant prostate cancer
- (2011) Celestia S. Higano et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
- (2010) Michael E. Jung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
- (2009) R. M. Attar et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
- (2009) Todd Morgan et al. CURRENT CANCER DRUG TARGETS
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
- (2009) Elahe A. Mostaghel et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started